Početna › Neuroblastom › Illinois
Kliničke studije za Neuroblastom u državi Illinois
6 studija za Neuroblastom traži sudionike na lokacijama u državi Illinois.
Gradovi u državi Illinois
Službeni tekst studije (engleski)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- i još 4
U tijeku regrutacijaFaza 3
Do 30 godina · Oba spola · Ažurirano 2. lis 2026. · NCT06172296International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE
- Ann & Robert H. Lurie Children's Hospital of Chicago and the Stanley Manne Children's Research Institute, Chicago
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 3. ruj 2026. · NCT03088020Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- i još 4
U tijeku regrutacijaFaza 3
365 Days – 30 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Lurie Children's Hospital-Chicago, Chicago
U tijeku regrutacijaFaza 1/2
12 Months – 30 Years · Oba spola · Ažurirano 25. kol 2026. · NCT04851119NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Comer Children's Hospital, University of Chicago, Chicago
U tijeku regrutacijaFaza 2
Od 1 do 31 godina · Oba spola · Ažurirano 20. srp 2026. · NCT06450041Neuroblastoma Biology Study
- University of Chicago, Comer Children's Hospital, Chicago
U tijeku regrutacijaOpažajna studija
31 Days – 99 Years · Oba spola · Ažurirano 23. ožu 2026. · NCT01587300Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.